Press releases
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2445 |
---|---|
High | 0.2615 |
Low | 0.2445 |
Bid | 0.235 |
Offer | 0.2515 |
Previous close | 0.276 |
Average volume | 18.08k |
---|---|
Shares outstanding | 64.45m |
Free float | 62.45m |
P/E (TTM) | -- |
Market cap | 17.18m USD |
EPS (TTM) | -0.5791 USD |
Data delayed at least 15 minutes, as of May 13 2024 11:54 BST.
More ▼